Drug Profile


Alternative Names: 1363089; EXEL-2880; GSK 089; GSK 1363089; GSK 1363089G; XL 880

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Exelixis
  • Developer GlaxoSmithKline; National Cancer Institute (Canada)
  • Class Anilides; Antineoplastics; Quinolines; Small molecules
  • Mechanism of Action Proto oncogene protein c met inhibitors; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Gastric cancer; Head and neck cancer; Liver cancer; Non-small cell lung cancer; Renal cancer

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 01 Mar 2015 GlaxoSmithKline completes a phase I trial for Liver cancer in Hong Kong, Taiwan, and Thailand (NCT00920192)
  • 01 Feb 2015 GlaxoSmithKline completes a phase I/II trial in Non-small cell lung cancer (Second-line therapy or greater, Late-stage disease) in Canada (NCT01068587)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top